213 related articles for article (PubMed ID: 25382104)
1. Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study.
Banavath HN; Sharma OP; Kumar MS; Baskaran R
Sci Rep; 2014 Nov; 4():6948. PubMed ID: 25382104
[TBL] [Abstract][Full Text] [Related]
2. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
Kumar H; Raj U; Gupta S; Varadwaj PK
J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
[TBL] [Abstract][Full Text] [Related]
3. In silico drug repurposing of FDA-approved drugs to predict new inhibitors for drug resistant T315I mutant and wild-type BCR-ABL1: A virtual screening and molecular dynamics study.
Sohraby F; Bagheri M; Aliyar M; Aryapour H
J Mol Graph Model; 2017 Jun; 74():234-240. PubMed ID: 28458002
[TBL] [Abstract][Full Text] [Related]
4. Ensemble-based virtual screening: identification of a potential allosteric inhibitor of Bcr-Abl.
Singh VK; Coumar MS
J Mol Model; 2017 Jul; 23(7):218. PubMed ID: 28669127
[TBL] [Abstract][Full Text] [Related]
5. In silico design and computational evaluation of novel 2-arylaminopyrimidine-based compounds as potential multi-targeted protein kinase inhibitors: application for the native and mutant (T315I) Bcr-Abl tyrosine kinase.
Koroleva EV; Kornoushenko YV; Karpenko AD; Bosko IP; Siniutsich JV; Ignatovich ZV; Andrianov AM
J Biomol Struct Dyn; 2023 Jun; 41(9):4065-4080. PubMed ID: 35470777
[TBL] [Abstract][Full Text] [Related]
6. Identification by molecular dynamic simulation and in vitro validation of SISB-A1, N-[1-(4-bromophenyl)-3-methyl-1H-pyrazol-5-yl]-2-[(2-oxo-4-phenyl-2H-chromen-7-yl) oxy], as an inhibitor of the Abl
Al Shahrani M; Gahtani RM; Abohassan M; Alasmari S; Makkawi M
Med Oncol; 2023 Oct; 40(11):316. PubMed ID: 37789230
[TBL] [Abstract][Full Text] [Related]
7. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
[TBL] [Abstract][Full Text] [Related]
8. Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors.
Singh VK; Chang HH; Kuo CC; Shiao HY; Hsieh HP; Coumar MS
J Biomol Struct Dyn; 2017 Jun; 35(8):1833-1848. PubMed ID: 27353341
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 2-Acylaminothiophene-3-Carboxamides as Multitarget Inhibitors for BCR-ABL Kinase and Microtubules.
Cao R; Wang Y; Huang N
J Chem Inf Model; 2015 Nov; 55(11):2435-42. PubMed ID: 26501568
[TBL] [Abstract][Full Text] [Related]
10. Discovery of picomolar ABL kinase inhibitors equipotent for wild type and T315I mutant via structure-based de novo design.
Park H; Hong S; Kim J; Hong S
J Am Chem Soc; 2013 Jun; 135(22):8227-37. PubMed ID: 23679864
[TBL] [Abstract][Full Text] [Related]
11. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
12. In silico identification of novel kinase inhibitors targeting wild-type and T315I mutant ABL1 from FDA-approved drugs.
Xu HL; Wang ZJ; Liang XM; Li X; Shi Z; Zhou N; Bao JK
Mol Biosyst; 2014 Jun; 10(6):1524-37. PubMed ID: 24691568
[TBL] [Abstract][Full Text] [Related]
13. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
14. Identification of natural inhibitors of Bcr-Abl for the treatment of chronic myeloid leukemia.
Parcha P; Sarvagalla S; Madhuri B; Pajaniradje S; Baskaran V; Coumar MS; Rajasekaran B
Chem Biol Drug Des; 2017 Oct; 90(4):596-608. PubMed ID: 28338290
[TBL] [Abstract][Full Text] [Related]
15. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
Kim JE; Yoon S; Choi BR; Kim KP; Cho YH; Jung W; Kim DW; Oh S; Kim DE
Leukemia; 2013 Aug; 27(8):1650-8. PubMed ID: 23434731
[TBL] [Abstract][Full Text] [Related]
16. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
[TBL] [Abstract][Full Text] [Related]
17. Identification of common inhibitors of wild-type and T315I mutant of BCR-ABL through the parallel structure-based virtual screening.
Park H; Hong S; Hong S
J Comput Aided Mol Des; 2012 Aug; 26(8):983-92. PubMed ID: 22886487
[TBL] [Abstract][Full Text] [Related]
18. Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant.
Hong S; Kim J; Yun SM; Lee H; Park Y; Hong SS; Hong S
J Med Chem; 2013 May; 56(9):3531-45. PubMed ID: 23600806
[TBL] [Abstract][Full Text] [Related]
19. Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template.
Zhou T; Commodore L; Huang WS; Wang Y; Sawyer TK; Shakespeare WC; Clackson T; Zhu X; Dalgarno DC
Chem Biol Drug Des; 2010 Jan; 75(1):18-28. PubMed ID: 19895503
[TBL] [Abstract][Full Text] [Related]
20. Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate.
Gray NS; Fabbro D
Methods Enzymol; 2014; 548():173-88. PubMed ID: 25399646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
